Blog

Blog

Drug Target Encyclopedia Series (37) —STEAP1

Linkedin

Release Time：

2026-04-24 09:48

 

  

STEAP1, also known as Six-Transmembrane Epithelial Antigen of the Prostate 1, is a tumor-associated cell surface antigen highly expressed in prostate cancer and several other solid tumors. With its multi-pass membrane structure and relatively restricted expression in normal tissues, STEAP1 has become an attractive target for next-generation oncology drug development.

STEAP1 is gaining strong attention in advanced prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC), where there remains a significant need for differentiated targets beyond existing prostate cancer therapies. Its membrane localization makes it highly relevant for antibody-based, cell therapy, and targeted delivery approaches.

 

🧬 STEAP1 is highly relevant in:

• Prostate cancer

• Metastatic castration-resistant prostate cancer (mCRPC)

• Ewing sarcoma

• Bladder cancer

• Colorectal cancer

• Breast cancer

• NSCLC and other solid tumor research

 

🎯 Targeting STEAP1 in oncology drug development:

🧪 Antibody-drug conjugates (ADCs) – STEAP1 provides a compelling surface antigen for tumor-selective payload delivery in solid tumors.

🧪 CAR-T cell therapy – STEAP1 CAR-T programs are being explored to address advanced prostate cancer, with preclinical studies showing antitumor activity in metastatic prostate cancer models.

🧪 T-cell engagers / bispecific antibodies – STEAP1-targeted T-cell redirecting strategies are emerging as a promising approach to drive immune-mediated tumor killing.

🧪 Radioligand and imaging strategies – STEAP1 may support new diagnostic, patient selection, and targeted radiotherapeutic approaches in prostate cancer.

🧪 Combination strategies – STEAP1-targeted modalities are being evaluated alongside androgen receptor pathway inhibition and other prostate cancer treatment backbones.

 

💥 Challenges include:

• Tumor antigen heterogeneity

• Antigen escape and resistance mechanisms

• Solid tumor microenvironment barriers

• Balancing potency with on-target/off-tumor safety

• Translating strong preclinical activity into durable clinical benefit

🔬 Ongoing research is positioning STEAP1 as one of the most promising membrane protein targets in prostate cancer and solid tumor therapeutics. As the field moves beyond single-target prostate cancer strategies, STEAP1 may play an important role in expanding the next generation of ADCs, bispecific antibodies, CAR-T therapies, and precision oncology platforms.

 

Need STEAP1 tools for your research?

 

Fill out the form below, or visit the link: to browse the complete list of available in-stock products.  

 

Prev

Drug Target Encyclopedia Series (38) —DLL3

Drug Target Encyclopedia Series (36) —CD152

Next